No sooner did Charles River report of its $1.6 B deal to acquire Wuxi Apptec's CRO business hit the street, PPD announced the opening of its new vaccine research center and claimed title of biggest CRO in China. See Fierce Biotech.
PPD opened its center in Taizhou China Medical City to enable it to conduct the world's largest vaccine trials but with shortened recruitment times due to easy access to study participants. The new center supports the fast growing vaccine market (> 20% CAGR).
Simon Britton, PPD's VP of clinical development for Asia Pacific, stated "Our strong expertise in vaccine clinical research and large presence in China make us well positoned to help our clients ensure adherence to global standards while addressing unique requirements for monitoring vaccine studies"
That's a lot of investment, and a lot of CRO activity in China for this week - or any week. But, as explained in FierceBiotech's story on China's CRO appeal, China's local authorities are willing to aggresively work with new businesses to meet their needs and make it happen. This according to Charles Rivers outgoing Chris Perkins.
China is less expensive to build in, has large, less expensive talent pools, far less expensive animal models, and regulators who want to help business. They also don't have any animal rights activists to harry labs and perhaps drive them underground as has happened in EU & US.
That's a number of good reasons for Big Pharma companies to do business with CRO's located in China - but who's counting.
Posted by Bruce Lehr April 28th 2010.